Annual Cash & Cash Equivalents
$23.77 M
-$461.00 K-1.90%
December 31, 2023
Summary
- As of February 8, 2025, RGLS annual cash & cash equivalents is $23.77 million, with the most recent change of -$461.00 thousand (-1.90%) on December 31, 2023.
- During the last 3 years, RGLS annual cash & cash equivalents has fallen by -$7.32 million (-23.55%).
- RGLS annual cash & cash equivalents is now -60.64% below its all-time high of $60.38 million, reached on December 31, 2021.
Performance
RGLS Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$26.37 M
+$9.25 M+54.03%
September 30, 2024
Summary
- As of February 8, 2025, RGLS quarterly cash and cash equivalents is $26.37 million, with the most recent change of +$9.25 million (+54.03%) on September 30, 2024.
- Over the past year, RGLS quarterly cash and cash equivalents has increased by +$9.25 million (+54.03%).
- RGLS quarterly cash and cash equivalents is now -56.32% below its all-time high of $60.38 million, reached on December 31, 2021.
Performance
RGLS Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
RGLS Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -1.9% | +54.0% |
| 3 y3 years | -23.6% | -24.9% |
| 5 y5 years | +70.6% | +80.1% |
RGLS Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -60.6% | at low | -56.3% | +54.0% |
| 5 y | 5-year | -60.6% | at low | -56.3% | +54.0% |
| alltime | all time | -60.6% | +159.0% | -56.3% | +435.2% |
Regulus Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $26.37 M(+54.0%) |
| Jun 2024 | - | $17.12 M(-42.1%) |
| Mar 2024 | - | $29.59 M(+24.5%) |
| Dec 2023 | $23.77 M(-1.9%) | $23.77 M(-8.0%) |
| Sep 2023 | - | $25.83 M(-30.7%) |
| Jun 2023 | - | $37.26 M(+22.9%) |
| Mar 2023 | - | $30.31 M(+25.1%) |
| Dec 2022 | $24.23 M(-59.9%) | $24.23 M(+21.1%) |
| Sep 2022 | - | $20.01 M(-43.0%) |
| Jun 2022 | - | $35.12 M(-34.8%) |
| Mar 2022 | - | $53.90 M(-10.7%) |
| Dec 2021 | $60.38 M(+94.2%) | $60.38 M(+68.4%) |
| Sep 2021 | - | $35.85 M(-13.5%) |
| Jun 2021 | - | $41.44 M(+31.2%) |
| Mar 2021 | - | $31.60 M(+1.6%) |
| Dec 2020 | $31.09 M(-8.9%) | $31.09 M(+74.2%) |
| Sep 2020 | - | $17.84 M(-23.8%) |
| Jun 2020 | - | $23.42 M(-16.5%) |
| Mar 2020 | - | $28.05 M(-17.8%) |
| Dec 2019 | $34.12 M(+144.9%) | $34.12 M(+133.0%) |
| Sep 2019 | - | $14.65 M(-25.2%) |
| Jun 2019 | - | $19.57 M(+89.6%) |
| Mar 2019 | - | $10.32 M(-25.9%) |
| Dec 2018 | $13.94 M | $13.94 M(-1.1%) |
| Sep 2018 | - | $14.08 M(+4.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2018 | - | $13.48 M(+34.1%) |
| Mar 2018 | - | $10.06 M(-25.6%) |
| Dec 2017 | $13.52 M(-9.5%) | $13.52 M(-33.1%) |
| Sep 2017 | - | $20.22 M(+61.3%) |
| Jun 2017 | - | $12.54 M(-15.8%) |
| Mar 2017 | - | $14.89 M(-0.3%) |
| Dec 2016 | $14.94 M(-6.4%) | $14.94 M(+1.6%) |
| Sep 2016 | - | $14.71 M(-45.6%) |
| Jun 2016 | - | $27.04 M(+40.5%) |
| Mar 2016 | - | $19.25 M(+20.6%) |
| Dec 2015 | $15.96 M(-57.2%) | $15.96 M(-12.9%) |
| Sep 2015 | - | $18.32 M(-13.1%) |
| Jun 2015 | - | $21.08 M(+7.6%) |
| Mar 2015 | - | $19.60 M(-47.5%) |
| Dec 2014 | $37.33 M(+109.6%) | $37.33 M(+274.8%) |
| Sep 2014 | - | $9.96 M(-0.7%) |
| Jun 2014 | - | $10.02 M(+18.3%) |
| Mar 2014 | - | $8.48 M(-52.4%) |
| Dec 2013 | $17.81 M(-56.1%) | $17.81 M(-46.8%) |
| Sep 2013 | - | $33.49 M(+74.7%) |
| Jun 2013 | - | $19.17 M(+7.6%) |
| Mar 2013 | - | $17.82 M(-56.1%) |
| Dec 2012 | $40.55 M(+342.0%) | $40.55 M(+132.7%) |
| Sep 2012 | - | $17.43 M(+253.6%) |
| Jun 2012 | - | $4.93 M(-46.3%) |
| Dec 2011 | $9.18 M | $9.18 M |
FAQ
- What is Regulus Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Regulus Therapeutics?
- What is Regulus Therapeutics annual cash & cash equivalents year-on-year change?
- What is Regulus Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Regulus Therapeutics?
- What is Regulus Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Regulus Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of RGLS is $23.77 M
What is the all time high annual cash & cash equivalents for Regulus Therapeutics?
Regulus Therapeutics all-time high annual cash & cash equivalents is $60.38 M
What is Regulus Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, RGLS annual cash & cash equivalents has changed by -$461.00 K (-1.90%)
What is Regulus Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of RGLS is $26.37 M
What is the all time high quarterly cash and cash equivalents for Regulus Therapeutics?
Regulus Therapeutics all-time high quarterly cash and cash equivalents is $60.38 M
What is Regulus Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, RGLS quarterly cash and cash equivalents has changed by +$9.25 M (+54.03%)